Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Combined With Lenalidomide in High Risk Relapsed or Refractory Mantle Cell Lymphoma
NCT07460362Phase 2Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in mantle cell lymphoma (MCL), sponsored by Peking University Third Hospital. Started Aug 2025; status: recruiting.
02
Drugs
glofitamab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07460362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07460362.